TCG Labs Soleil, a venture firm specializing in creating single-drug biotechnology startups, secured an additional $400 million, doubling its initial fund to $800 million. The firm also launched operations in Shanghai to expand its R&D capabilities. Since founding, TCG Labs Soleil has established 10 portfolio companies focused on diverse therapeutic areas including oncology and immune diseases. This infusion supports accelerated program development and strategic partnerships, signaling growing investment interest in nimble, capital-efficient biotech startup models.